Answers are grounded in this paper and cite their sources.
This research assesses B cell changes after controlled malaria infection in individuals with varying malaria immunity, suggesting immunity influences immune response.
Continuous exposure to Plasmodium falciparum (Pf) has been associated with alterations in B cells. We investigated the effect of controlled human malaria infection (CHMI) on B cell phenotypes in individuals with different Pf immunity status: malaria-naïve, immunized with PfSPZ-CVac and semi-immune (lifelong-exposed) volunteers. Compared to naïve, semi-immune but not vaccinated individuals, had increased baseline frequencies of immature B cells (CD19 + CD10 + ), active naive (IgD + CD27 − CD21 − ) B cells, active atypical (IgD − CD27 − CD21 − ) memory B cells (MBCs), active classical (IgD − CD27 + CD21 − ) MBCs and CD1c + -B cells but lower frequencies of some IgG + -B cells. The frequencies of CD1c + active atypical MBCs correlated positively with anti-Pf antibodies and negatively with circulating eotaxin levels, while the opposite was observed for IgG + resting atypical MBCs. During early blood-stage infection (day 11 after CHMI), there was an expansion of resting classical (IgD − CD27 + CD21 + ) MBCs in all three groups. Vaccination, compared to placebo, altered the effect of CHMI on B cells, showing a positive association with resting classical MBCs (β = 0.190, 95% CI 0.011–0.368) and active naïve-PD1 + (β = 0.637, 95% CI 0.058 to 1.217) frequencies, and a negative one with CD1c + resting atypical MBCs (β = − 0.328, 95% CI − 0.621 to − 0.032). In addition, the sickle cell trait in semi-immune subjects altered the effect of CHMI on several B cells. In conclusion, lifelong but not vaccine exposure to malaria was associated with increased frequencies of multiple B cell subsets, with higher and lower percentages of CD1c and IgG expressing-cells, respectively. A single infection (CHMI) induces changes in B cell frequencies and is modulated by sickle cell trait and malaria-immunity status. Clinical Trials Registration NCT01624961, NCT02115516, and NCT02237586.
No takes yet. Share an insight, caveat, or question.
Requena et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: